Actively Recruiting
Acceptability of a Virtual Reality-Based Training for Inhibitory Control in Older Adults With Neurocognitive Disorders
Led by Centre Hospitalier Universitaire de Nice · Updated on 2024-11-20
48
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the acceptability of an immersive virtual reality (VR) application designed to improve inhibitory control in older adults diagnosed with neurocognitive disorders. This study focuses on patients aged 60 and older who experience difficulties with executive functions, particularly inhibitory control. The trial compares traditional and new technological tools, aiming to understand how patients respond to these interventions using immersive and non-immersive formats. Participants will be randomly assigned to either an immersive VR headset group or a non-immersive tablet group. Each participant will engage in eight 20-minute sessions over four weeks, playing a serious game based on the GoNoGo task that challenges inhibitory control. The study includes a follow-up period where participants will repeat the sessions two months after enrollment to assess continued acceptability and engagement with the intervention. Throughout the study, participants will complete questionnaires at multiple time points, including at the start, during, and several weeks after the intervention to measure acceptability using the Unified Theory of Acceptance and Use of Technology 2 (UTAUT2) questionnaire. The research team will monitor how participants interact with the technology, their ability to complete the tasks, and their responses to the questionnaires over a total period spanning 24 weeks. This will help evaluate the practical use of VR and tablet-based serious games for inhibitory control training in this population.
CONDITIONS
Brief Title
Virtual Reality Training for Inhibitory Control in Neurocognitive Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Consulting the Nice hospital Memory Center
- Diagnosis of Mild Neurocognitive Disorder or slight major neurocognitive disorder (DSM V)
- 60 years old or more
- Presence of deficits in inhibitory control as assessed by the Frontal Assessment Battery
- Fluent in French
- Able to understand the informed consent form and voluntarily consents to participate
You will not qualify if you...
- Presence of significant vision or motor problems which would impact ability to perform the task
- Significant self-reported motion sickness
- Vulnerable persons as defined in articles L1121-5 to 8 of the French Public Health Code
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 4 weeks
Participants complete 8 sessions of 20 minutes playing the serious game either with a VR headset or on a tablet, twice a week for 4 weeks.
8 sessions over 4 weeks (twice weekly)
Duration - 4 weeks starting 2 months after enrollment
Participants in the waiting groups begin 8 sessions of 20 minutes playing the serious game with a VR headset or tablet, twice a week for 4 weeks, starting 2 months after enrollment.
8 sessions over 4 weeks (twice weekly)
Duration - Up to 24 weeks
Participants complete questionnaires assessing technology acceptance at multiple time points up to 24 weeks after enrollment.
Questionnaires at 0, 4, 8, 16, 20, and 24 weeks
Trial Site Locations
Total: 1 location
1
CHU de Nice
Nice, France, 06000
Actively Recruiting
Research Team
L
Lemaire Justine
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here